Outset Medical, Inc. (OM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.59+0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Outset aims to grow revenue to about $127.5 million in 2026. Profit margins should stay near 45% by year-end. A new deal with HCA could grow customers. These steps can help the company improve from losses.
Revenue growth is slow and profit margins are weak. The company keeps missing earnings. Leadership changes may hurt progress. Losses could continue for years.
The market has no clear consensus or price target. Estimates show losses continuing through 2027. Our view is cautious but sees potential if growth and margins improve.
Breaks if: gross margin falls below 40% in 2026
Sustain non-GAAP gross margin between low-40% and mid-40% range throughout 2026 to improve profitability.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround play with a focus on improving fundamentals but faces significant challenges. The current thesis is cautious, given the company's recent earnings misses and high risk factors.
The market appears to be pricing in a cautious outlook, as the company has been loss-making and has missed earnings expectations recently. There is an expectation for continued pressure unless management can deliver on growth targets and improve overall financial performance.
Management is on track to achieve its revenue guidance and maintain gross margins, but the company has a high probability of missing earnings in the near term. Recent changes in company quality show improvement, but execution risks remain elevated.
The thesis hinges on management's ability to meet revenue targets and maintain margins while navigating potential earnings misses. Additionally, broader sector performance, particularly from key players, could influence OM's trajectory positively or negatively.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Non-GAAP gross margin improved from 38.0% in first half 2025 to 43.0% in first half 2026, consistent with guidance to maintain low to mid-40% range. The trajectory is delivering with margin expansion.
“The Company continues to expect non-GAAP gross margin to range between the low-40% to mid-40% range for the full year.”
“non-GAAP gross margin guidance in the low to mid-40% range for the year”
“non-GAAP gross margin guidance in the low to mid-40% range for the year”
Breaks if: no revenue growth or customer gains from HCA refresh by end 2026
Grow recurring revenue and backlog by executing a three-year, $40 million fleet refresh agreement with HCA Healthcare.
Newly stated in 2026-Q2. The company signed a three-year, $40 million fleet refresh agreement with HCA Healthcare, aiming to expand its customer base and backlog. This is a recent development with limited financial impact visible yet, indicating early stage execution.
“Signed a three-year, $40 million agreement with HCA Healthcare to refresh the existing fleet of Tablo systems”
Breaks if: annual revenue falls below $125 million in 2026
Continue to grow revenue to meet the 2026 guidance range of $125 million to $130 million, reflecting a 5% to 9% increase over 2025.
Stated as a priority in 3 of last 3 quarters. Revenue was $119.5 million in 2025 with 2026 guidance reiterated at $125 million to $130 million, targeting a 5% to 9% increase. Recent quarterly revenue showed slight fluctuations but the company is maintaining its growth guidance, indicating delivering trajectory.
“Outset reiterated its 2026 revenue guidance of $125 million to $130 million”
“Outset reiterated its 2026 revenue guidance of $125 million to $130 million”
“Outset provided 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025”
In the next 1 to 3 years, OM's outlook will depend on its execution against guidance and the overall health of the healthcare sector. Not investment advice.